Erratum: Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study (Gene Therapy, (2016), 23, 8-9, (690-695), 10.1038/gt.2016.41);Excision of HIV-1 DNA by gene editing: A proof-of-concept in vivo study

Gene Therapy

Volumn 23, Issue 8-9, 2016, Pages 690-695

  Kaminski, R ^a   Bella, R ^b   Yin, C ^a   Otte, J ^a   Ferrante, P ^b   Gendelman, H E ^c   Li, H ^d   Booze, R ^d   Gordon, J ^a   Hu, W ^a   Khalili, K ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA FRAGMENT; GUIDE RNA; VIRUS DNA; GAG PROTEIN;

5' UNTRANSLATED REGION; ADENO ASSOCIATED VIRUS 9; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CRISPR CAS SYSTEM; DNA SEQUENCE; DNA VIRUS; EMBRYO; GAG GENE; GENE; GENE EXPRESSION; GENE TARGETING; HEART; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VIVO STUDY; KIDNEY; LIVER; LUNG; LYMPHOCYTE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SPLEEN; TRANSGENIC MOUSE; TRANSGENIC RAT; VIRUS GENOME; VIRUS RECOMBINANT; ANIMAL; CARDIAC MUSCLE; CD4+ T LYMPHOCYTE; CELL CULTURE; DEPENDOPARVOVIRUS; GENE EDITING; GENETICS; METABOLISM; PROCEDURES; RAT;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CRISPR-CAS SYSTEMS; DEPENDOVIRUS; DNA, VIRAL; GENE EDITING; GENE PRODUCTS, GAG; GENE TARGETING; HIV-1; KIDNEY; LIVER; LUNG; MICE; MYOCARDIUM; RATS;

EID: 84969706258     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2016.45     Document Type: Erratum

References (29)

1. Adejumo OA, Malee KM, Ryscavage P, Hunter SJ, Taiwo BO. Contemporary issues on the epidemiology and antiretroviral adherence of HIV-infected adolescents in sub-Saharan Africa: a narrative review. J Int AIDS Soc 2015; 18: 20049.
2. Kulpa DA, Chomont N. HIV persistence in the setting of antiretroviral therapy: when, where and how does HIV hide? J Virus Erad 2015; 1: 59-66.
3. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995; 267: 483-489.
4. Coffin JM. HIV viral dynamics. AIDS 1996; 10: S75-S84.
5. Saleh S, Solomon A, Wightman F, Xhilaga M, Cameron PU, Lewin SR. CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood 2007; 110: 4161-4164.
6. Swiggard WJ, Baytop C, Yu JJ, Dai J, Li C, Schretzenmair R. Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. J Virol 2005; 79: 141799-14188.
7. Lusic M, Giacca M. Regulation of HIV-1 latency by chromatin structure and nuclear architecture. J Mol Biol 2015; 427: 688-694.
8. Hu W, Kaminski R, Yang F, Zhang Y, Cosentino L, Li F et al. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci USA 2014; 111: 11461-11466.
9. Khalili K, Kaminski R, Gordon J, Cosentino L, Hu W. Genome editing strategies: potential tools for eradicating HIV-1/AIDS. J Neurovirol 2015; 21: 310-321.
10. Ebina H, Misawa N, Kanemura Y, Koyanagi Y. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep 2013; 3: 2510.
11. Liao HK, Gu Y, Diaz A, Marlett J, Takahashi Y, Li M et al. Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells. Nat Commun 2015; 6: 6413.
12. Zhu W, Lei R, Le Duff Y, Li J, Guo F, Wainberg MA et al. The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA. Retrovirology 2015; 12: 22.
13. Mittermeyer G, Christine CW, Rosenbluth KH, Baker SL, Starr P, Larson P et al. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. Hum Gene Ther 2012; 23: 377-381.
14. Boudreau RL, Rodriguez-Lebrón E, Davidson BL. RNAi medicine for the brain: progresses and challenges. Hum Mol Genet 2011; 20: R21-R27.
15. Naldini L. Gene therapy returns to centre stage. Nature 2015; 526: 351-360.
16. Bennett J, Ashtari M, Wellman J, Marshall KA, Cyckowski LL, Chung DC et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med 2012; 4: 120ra15.
17. Janson C, McPhee S, Bilaniuk L, Haselgrove J, Testaiuti M, Freese A et al. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther 2002; 13: 1391-1412.
18. Curreli S, Krishnan S, Reitz M, Lunardi-Iskandar Y, Lafferty MK, Garzino-Demo A et al. B cell lymphoma in HIV transgenic mice. Retrovirology 2013; 10: 92.
19. Kopp JB, Klotman ME, Adler SH, Bruggeman LA, Dickie P, Marinos NJ et al. Progressive glomerulosclerosis and enhanced renal accumulation of basement membrane components in mice transgenic for human immunodeficiency virus type 1 genes. Proc Natl Acad Sci USA 1992; 89: 1577-1581.
20. Santoro TJ, Bryant JL, Pellicoro J, Klotman ME, Kopp JB, Bruggeman LA et al. Growth failure and AIDS-like cachexia syndrome in HIV-1 transgenic mice. Virology 1994; 201: 147-151.
21. Barisoni L, Bruggeman LA, Mundel P, D'Agati VD, Klotman PE. HIV-1 induces renal epithelial dedifferentiation in a transgenic model of HIV-associated nephropathy. Kidney Int 2000; 58: 173-181.
22. Dickie P, Felser J, Eckhaus M, Bryant J, Silver J, Marinos N et al. HIV-associated nephropathy in transgenic mice expressing HIV-1 genes. Virology 1991; 185: 109-119.
23. Ran FA, Cong L, Yan WX, Scott DA, Gootenberg JS, Kriz AJ et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 2015; 520: 186-191.
24. Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 2014; 346: 1258096.
25. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 2014; 157: 1262-1278.
26. White MK, Hu W, Khalili K. The CRISPR/Cas9 genome editing methodology as a weapon against human viruses. Discov Med 2015; 19: 255-262.
27. White MK, Khalili K. CRISPR/Cas9 and cancer targets: future possibilities and present challenges. Oncotarget 2016; 7: 12305-12317.
28. Kaminski R, Chen Y, Fischer T, Tedaldi E, Napoli A, Zhang Y et al. Elimination of HIV-1 genomes from human T-lymphoid cells by CRISPR/Cas9 gene editing. Sci Rep 2016; 6: 22555.
29. Behringer R. Manipulating the Mouse Embryo: a Laboratory Manual, 4th edn. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, USA, 2014.